A novel de novo mutation in the desmin gene causes desmin myopathy with toxic aggregates

M Sugawara1, K Kato, M Komatsu

  • 1First Department of Internal Medicine, Akita University School of Medicine, Hondo, Japan. masashir@med.akita-u.ac.jp

Neurology
|November 4, 2000
PubMed
Abstract

Insights

A novel de novo mutation, L385P, causes desmin myopathy, a skeletal myopathy often linked to cardiomyopathy. This genetic defect leads to toxic effects on muscle cells, resulting in severe muscle weakness and cardiac issues.

Area of Science:

  • Genetics and Molecular Biology
  • Cardiology
  • Neurology

Background:

  • Desmin myopathy is a myofibrillar myopathy linked to desmin gene mutations, characterized by desmin protein accumulation.
  • Mutations in the desmin gene can lead to skeletal myopathy and cardiomyopathy.

Observation:

  • A 21-year-old patient presented with progressive cardioskeletal myopathy, starting with distal limb weakness and later involving cardiac and facial muscles.
  • Muscle biopsy revealed sarcomere disruption and desmin aggregates in skeletal and cardiac muscle tissue.

Findings:

  • A novel de novo mutation, L385P, in the desmin gene was identified in the patient.
  • Expression studies demonstrated that the L385P mutation induces toxic effects, including protein aggregation, DNA condensation, and cell death.

Implications:

  • This study identifies a new genetic cause for desmin myopathy and elucidates the pathogenic mechanism.
  • Understanding the toxic effects of specific desmin mutations can inform future therapeutic strategies for myofibrillar myopathies.